CXCR2 is involved in therapy resistance by maintaining and promoting the migration of cancer stem cells (CSCs), and it is not only suggested as a novel cancer stem-like cell marker for TNBC (Wang et al., 2018) but also known to regulate TGF-β signaling, which is known to promote chemotherapy resistance (Mohammad et al., 2015). This evidence concerns the gene CXCR2 and cancer.